RYTM on XNAS, Health Care, Rhythm Pharmaceuticals, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue jumped 80% to $92.1M while twelve-month losses reached $193.8M.
BadShort interest at 17% of shares, 23.3 days to cover
GoodInstitutional holders rose 10%, from 298 to 328 in a quarter
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
expected around 8 Jan 2027 (an estimate: a year ago it reported on 9 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $92.1M, net loss $41.4M.
31 Dec 2021RevenueNet incomeNet losstallest bar $141.4M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$92.1M
-$41.4M
30 Jun 2026
$71.3M
-$49.3M
31 Mar 2026
$60.1M
-$55.6M
31 Dec 2025
$57.3M
-$47.5M
30 Sep 2025
$51.3M
-$52.9M
30 Jun 2025
$48.5M
-$46.6M
31 Mar 2025
$32.7M
-$49.5M
31 Dec 2024
$41.8M
-$43.3M
30 Sep 2024
$33.3M
-$43.6M
30 Jun 2024
$29.1M
-$32.3M
31 Mar 2024
$26.0M
-$141.4M
31 Dec 2023
$24.2M
-$41.6M
30 Sep 2023
$22.5M
-$44.2M
30 Jun 2023
$19.2M
-$46.7M
31 Mar 2023
$11.5M
-$52.2M
31 Dec 2022
$8.8M
-$42.5M
30 Sep 2022
$4.3M
-$40.9M
30 Jun 2022
$9.1M
-$45.0M
31 Mar 2022
$1.5M
-$52.8M
31 Dec 2021
–
-$42.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$280.7M
$174.3M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+61%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$193.8M
-$192.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$2.90
-$3.10
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
88.2%
89.4%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-66.7%
-107%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-69.0%
-110%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-164%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$320.9M
$416.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$102.7M
$109.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$218.3M (net cash)
-$307.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
1.2
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.27
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
27.7
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
27.0
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
88.6
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$18.4M
bought $0, sold $18.4M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+10%
328 13F filers vs 298
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
78.9M shares held by 13F filers (30 Sep 2026) of 69.3M outstanding (2 Nov 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
17%
11.7M shares sold short (30 Oct 2026) of 69.3M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
23.3
11.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+6.1%
11.0M shares sold short in the report before, 11.7M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
35%
35% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 61%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+80%
$92.1M vs $51.3M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
35
35 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
18×
35 articles in the last 7 days; its usual week has 2.
Unusual now sharp changes in the last 90 days, compared with its own past
Revenue $92.1M, 1.8× a year earlier
Price $112.36 on 20 Nov 2026, +12% over 12 months (12-month range $75.82 to $119.04)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders sold a net $42.6M in the last 12 months (the 12 months before: -$35.5M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months, -100% on the 12 months before.Revenue per quarter. Revenue $92.1M in the latest quarter, +80% on a year earlier.Capital spending per quarter. Capital spending $953K in the latest quarter.Institutional holders (13F filers). 328 13F filers reported holding it in the latest 13F quarter, +31% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.
Two or more unrelated kinds of records unusual within 30 days
8 Aug 2023confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Rhythm Pharmaceuticals(RYTM): reported revenue of $19.2M for the quarter ended 30 Jun 2023, 2.1× the same quarter last year, while it had 12.4M shares sold short in the 31 Jul 2023 report, 1.7× the same report last year. Two unrelated kinds of activity within 42 days.
Short interest and volume: Short interest spike, became public on 13 Jul 2023
Short interest and volume: Short interest spike, became public on 26 Jul 2023
Financials: Quarterly revenue change, became public on 8 Aug 2023
Short interest and volume: Short interest spike, became public on 10 Aug 2023
Short interest and volume: Short interest spike, became public on 25 Aug 2023
The quarter ended 30 Jun 2023 against the 7 quarters before it.
this quarterearliernormal: $1.5MSee the evidence (5 changes)
Short interest and volume: Short interest spike became public on 13 Jul 2023
Rhythm Pharmaceuticals had 11.0M shares sold short in the 30 Jun 2023 report, 3.5× the same report last year.
This period
11.0M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
506K
How far from its usual level
+3.9
Same report last year
3.2M
History used
2,009 days
the 30 Jun 2023 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jul 2023
Rhythm Pharmaceuticals had 11.5M shares sold short in the 14 Jul 2023 report, 1.9× the same report last year.
This period
11.5M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
8.0M
Typical spread (median absolute deviation)
435K
How far from its usual level
+4.4
Same report last year
5.9M
History used
2,023 days
the 14 Jul 2023 report24 earlier reportsnormal: 8.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 8 Aug 2023
Rhythm Pharmaceuticals reported revenue of $19.2M for the quarter ended 30 Jun 2023, 2.1× the same quarter last year.
This period
$19.2M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$1.5M
Typical spread (median absolute deviation)
$1.5M
How far from its usual level
+8.2
Same quarter last year
$9.1M
History used
821 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $1.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2023
Rhythm Pharmaceuticals had 12.4M shares sold short in the 31 Jul 2023 report, 1.7× the same report last year.
This period
12.4M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
411K
How far from its usual level
+5.4
Same report last year
7.2M
History used
2,040 days
the 31 Jul 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Aug 2023
Rhythm Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 2.0× the same report last year.
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
413K
How far from its usual level
+3.5
Same report last year
5.6M
History used
2,055 days
the 15 Aug 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
5 Nov 2026Financials change
reported revenue of $92.1M for the quarter ended 30 Sep 2026, 1.8× the same quarter last year.
Same quarter last year: $51.3M; its normal quarter is $49.9M.
See the evidence
This period
$92.1M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$49.9M
Typical spread (median absolute deviation)
$9.1M
How far from its usual level
+3.1
Same quarter last year
$51.3M
History used
2,009 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $49.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.6M shares sold short in the 31 Mar 2026 report, 1.6× the same report last year.
Same report last year: 4.7M; its normal report is 5.2M.
See the evidence
This period
7.6M (the 31 Mar 2026 report)
Normal report (median of 24 earlier)
5.2M
Typical spread (median absolute deviation)
405K
How far from its usual level
+4.0
Same report last year
4.7M
History used
3,014 days
the 31 Mar 2026 report24 earlier reportsnormal: 5.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.8M shares sold short in the 13 Oct 2023 report, 1.5× the same report last year.
Same report last year: 7.6M; its normal report is 8.4M.
See the evidence
This period
11.8M (the 13 Oct 2023 report)
Normal report (median of 24 earlier)
8.4M
Typical spread (median absolute deviation)
631K
How far from its usual level
+3.6
Same report last year
7.6M
History used
2,114 days
the 13 Oct 2023 report24 earlier reportsnormal: 8.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 12.0M shares sold short in the 15 Sep 2023 report, 2.0× the same report last year.
Same report last year: 6.0M; its normal report is 8.2M.
See the evidence
This period
12.0M (the 15 Sep 2023 report)
Normal report (median of 24 earlier)
8.2M
Typical spread (median absolute deviation)
469K
How far from its usual level
+4.7
Same report last year
6.0M
History used
2,086 days
the 15 Sep 2023 report24 earlier reportsnormal: 8.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.0M shares sold short in the 15 Aug 2023 report, 2.0× the same report last year.
Same report last year: 5.6M; its normal report is 8.1M.
See the evidence
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
413K
How far from its usual level
+3.5
Same report last year
5.6M
History used
2,055 days
the 15 Aug 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 12.4M shares sold short in the 31 Jul 2023 report, 1.7× the same report last year.
Same report last year: 7.2M; its normal report is 8.1M.
See the evidence
This period
12.4M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
411K
How far from its usual level
+5.4
Same report last year
7.2M
History used
2,040 days
the 31 Jul 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $19.2M for the quarter ended 30 Jun 2023, 2.1× the same quarter last year, while it had 12.4M shares sold short in the 31 Jul 2023 report, 1.7× the same report last year. Two unrelated kinds of activity within 42 days.
See the evidence (5 changes)
Short interest and volume: Short interest spike became public on 13 Jul 2023
Rhythm Pharmaceuticals had 11.0M shares sold short in the 30 Jun 2023 report, 3.5× the same report last year.
This period
11.0M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
506K
How far from its usual level
+3.9
Same report last year
3.2M
History used
2,009 days
the 30 Jun 2023 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jul 2023
Rhythm Pharmaceuticals had 11.5M shares sold short in the 14 Jul 2023 report, 1.9× the same report last year.
This period
11.5M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
8.0M
Typical spread (median absolute deviation)
435K
How far from its usual level
+4.4
Same report last year
5.9M
History used
2,023 days
the 14 Jul 2023 report24 earlier reportsnormal: 8.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 8 Aug 2023
Rhythm Pharmaceuticals reported revenue of $19.2M for the quarter ended 30 Jun 2023, 2.1× the same quarter last year.
This period
$19.2M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$1.5M
Typical spread (median absolute deviation)
$1.5M
How far from its usual level
+8.2
Same quarter last year
$9.1M
History used
821 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $1.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2023
Rhythm Pharmaceuticals had 12.4M shares sold short in the 31 Jul 2023 report, 1.7× the same report last year.
This period
12.4M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
411K
How far from its usual level
+5.4
Same report last year
7.2M
History used
2,040 days
the 31 Jul 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Aug 2023
Rhythm Pharmaceuticals had 11.0M shares sold short in the 15 Aug 2023 report, 2.0× the same report last year.
This period
11.0M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
8.1M
Typical spread (median absolute deviation)
413K
How far from its usual level
+3.5
Same report last year
5.6M
History used
2,055 days
the 15 Aug 2023 report24 earlier reportsnormal: 8.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
8 Aug 2023Financials change
reported revenue of $19.2M for the quarter ended 30 Jun 2023, 2.1× the same quarter last year.
Same quarter last year: $9.1M; its normal quarter is $1.5M.
See the evidence
This period
$19.2M (the quarter ended 30 Jun 2023)
Normal quarter (median of 7 earlier)
$1.5M
Typical spread (median absolute deviation)
$1.5M
How far from its usual level
+8.2
Same quarter last year
$9.1M
History used
821 days
the quarter ended 30 Jun 20237 earlier quartersnormal: $1.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 11.5M shares sold short in the 14 Jul 2023 report, 1.9× the same report last year.
Same report last year: 5.9M; its normal report is 8.0M.
See the evidence
This period
11.5M (the 14 Jul 2023 report)
Normal report (median of 24 earlier)
8.0M
Typical spread (median absolute deviation)
435K
How far from its usual level
+4.4
Same report last year
5.9M
History used
2,023 days
the 14 Jul 2023 report24 earlier reportsnormal: 8.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.0M shares sold short in the 30 Jun 2023 report, 3.5× the same report last year.
Same report last year: 3.2M; its normal report is 7.9M.
See the evidence
This period
11.0M (the 30 Jun 2023 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
506K
How far from its usual level
+3.9
Same report last year
3.2M
History used
2,009 days
the 30 Jun 2023 report24 earlier reportsnormal: 7.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.4M shares sold short in the 15 Nov 2022 report, 2.2× the same report last year.
Same report last year: 3.8M; its normal report is 4.0M.
See the evidence
This period
8.4M (the 15 Nov 2022 report)
Normal report (median of 24 earlier)
4.0M
Typical spread (median absolute deviation)
567K
How far from its usual level
+5.2
Same report last year
3.8M
History used
1,782 days
the 15 Nov 2022 report24 earlier reportsnormal: 4.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.4M shares sold short in the 31 Oct 2022 report, 2.1× the same report last year.
Same report last year: 3.9M; its normal report is 3.9M.
See the evidence
This period
8.4M (the 31 Oct 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
476K
How far from its usual level
+6.3
Same report last year
3.9M
History used
1,767 days
the 31 Oct 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 14 Oct 2022 report, 2.0× the same report last year.
Same report last year: 3.9M; its normal report is 3.9M.
See the evidence
This period
7.6M (the 14 Oct 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
389K
How far from its usual level
+6.4
Same report last year
3.9M
History used
1,750 days
the 14 Oct 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 30 Sep 2022 report, 2.1× the same report last year.
Same report last year: 3.7M; its normal report is 3.9M.
See the evidence
This period
7.6M (the 30 Sep 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
274K
How far from its usual level
+9.3
Same report last year
3.7M
History used
1,736 days
the 30 Sep 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.0M shares sold short in the 15 Sep 2022 report, 1.6× the same report last year.
Same report last year: 3.7M; its normal report is 3.9M.
See the evidence
This period
6.0M (the 15 Sep 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
266K
How far from its usual level
+5.5
Same report last year
3.7M
History used
1,721 days
the 15 Sep 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.8M shares sold short in the 31 Aug 2022 report, 1.4× the same report last year.
Same report last year: 4.1M; its normal report is 3.9M.
See the evidence
This period
5.8M (the 31 Aug 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
266K
How far from its usual level
+4.9
Same report last year
4.1M
History used
1,706 days
the 31 Aug 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.6M shares sold short in the 15 Aug 2022 report, 1.3× the same report last year.
Same report last year: 4.4M; its normal report is 3.9M.
See the evidence
This period
5.6M (the 15 Aug 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
266K
How far from its usual level
+4.4
Same report last year
4.4M
History used
1,690 days
the 15 Aug 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 29 Jul 2022 report, 1.5× the same report last year.
Same report last year: 4.8M; its normal report is 3.9M.
See the evidence
This period
7.2M (the 29 Jul 2022 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
266K
How far from its usual level
+8.6
Same report last year
4.8M
History used
1,673 days
the 29 Jul 2022 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.9M shares sold short in the 15 Jul 2022 report, 1.4× the same report last year.
Same report last year: 4.4M; its normal report is 3.8M.
See the evidence
This period
5.9M (the 15 Jul 2022 report)
Normal report (median of 24 earlier)
3.8M
Typical spread (median absolute deviation)
171K
How far from its usual level
+5.6
Same report last year
4.4M
History used
1,659 days
the 15 Jul 2022 report24 earlier reportsnormal: 3.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.5M shares sold short in the 14 May 2021 report, 2.0× the same report last year.
Same report last year: 1.8M; its normal report is 2.0M.
See the evidence
This period
3.5M (the 14 May 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
261K
How far from its usual level
+3.9
Same report last year
1.8M
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.6M shares sold short in the 30 Apr 2021 report, 2.5× the same report last year.
Same report last year: 1.4M; its normal report is 2.0M.
See the evidence
This period
3.6M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
225K
How far from its usual level
+5.0
Same report last year
1.4M
History used
1,218 days
the 30 Apr 2021 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.7M shares sold short in the 15 Apr 2021 report, 2.1× the same report last year.
Same report last year: 1.7M; its normal report is 1.9M.
See the evidence
This period
3.7M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
178K
How far from its usual level
+6.5
Same report last year
1.7M
History used
1,203 days
the 15 Apr 2021 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.2M shares sold short in the 31 Mar 2021 report, 2.1× the same report last year.
Same report last year: 2.0M; its normal report is 1.9M.
See the evidence
This period
4.2M (the 31 Mar 2021 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
162K
How far from its usual level
+9.2
Same report last year
2.0M
History used
1,188 days
the 31 Mar 2021 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.7M shares sold short in the 15 Mar 2021 report, 1.7× the same report last year.
Same report last year: 1.6M; its normal report is 1.9M.
See the evidence
This period
2.7M (the 15 Mar 2021 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
150K
How far from its usual level
+3.5
Same report last year
1.6M
History used
1,172 days
the 15 Mar 2021 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.7M shares sold short in the 26 Feb 2021 report, 1.2× the same report last year.
Same report last year: 2.3M; its normal report is 1.9M.
See the evidence
This period
2.7M (the 26 Feb 2021 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
150K
How far from its usual level
+3.7
Same report last year
2.3M
History used
1,155 days
the 26 Feb 2021 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 86 entries; narrow the window or the kind of data to see older ones.
Not listed: 297 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001649904
Ticker
RYTM
Domain
rhythmtx.com
Employer name
Rhythm Pharmaceuticals, Inc. (1 unverified)
Hq location
MA|BOSTON|02116 (1 unverified)
Name
RHYTHM METABOLIC, INC., Rhythm Pharmaceuticals Canada Inc, Rhythm Pharmaceuticals France SAS, Rhythm Pharmaceuticals Germany GmbH and 9 more
Uei
G9KGU2YDQNU4
Wikidata
Q30269284
DOL H-1B labor condition applications and PERM certifications35 data points14 Feb 2022 to 27 Jul 2026
SEC Form 13F institutional holdings324 data points31 Dec 2017 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)141 records20 Jan 2017 to 3 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)678 data points31 Dec 2014 to 2 Nov 2026
SEC Form 4 insider transactions194 records, 480 data points6 Oct 2017 to 20 Nov 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards12 data points10 Jul 2015 to 8 Jul 2021